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Abstract The Fifth International Workshop on the CCN
Family of Genes was held in Toronto October 18–22, 2008.
This bi-annual workshop provides a unique opportunity for
the presentation and discussion of cutting edge research in
the CCN field. The CCN family members have emerged as
extracellular matrix associated proteins which play a crucial
role in cardiovascular and skeletal development, fibrosis
and cancer. Significant progress has been made in the
development of model systems to tease apart the CCN
signalling pathways in these systems. Results presented at
the conference suggest that targeting these pathways now
shows real promise as a therapeutic strategy.
Keywords CCN1.CCN2.CCN3.CCN4.CCN5.CCN6.
Cyr61.CTGF.NOV.Wisp-1.Wisp-2.Wisp-3
The Fifth International Workshop on the CCN Family of
Genes was held in Toronto October 18–22, 2008. The
meeting was organised by Herman Yeger, Bernard and
Annick Perbal and provided an excellent environment for
discussion and interaction amongst a diverse and enthusi-
astic group of researchers.
The Journal of Communication and Cell Signalling has
now been launched as the official journal of the Interna-
tional CCN Society. The publishers, Springer Science &
Business Media, sponsored the opening plenary session of
the conference and also three scholarships for young
investigators to attend the meeting. The first Springer
Award for outstanding research in this field was presented
by Peter Butler (Springer) to Professor Paul Bornstein for
his work on matricellular proteins. Professor Bornstein
gave a stimulating talk focussed on the concept of ‘dynamic
reciprocity’ and presented his studies using thrombospon-
din (TSP-1 and TSP-2) null mice. Opening remarks by
Professor Perbal coupled with Professor Bornstein’s lecture
set the stage nicely for the meeting to follow.
The first session of the meeting on CCN Structure/
Function and Expression opened with a presentation by Dr
Ravi Acharya (Bath, England). Dr Acharya examined the
protein structure of the CCN family and discussed how this
might contribute to the functional differences between
family members. By modelling the three dimensional
structure of the domains he provided insight as to how this
might influence interaction with other key molecules. This
was followed by a series of presentations on CCN2 gene
regulation lead by Dr Satoshi Kubota (Okayama, Japan)
who described the characterisation of Nucleophosmin/B23
as a regulator of CCN2 in chicken chondrocytes. Nucleo-
phosmin has the ability to shuttle between the nucleus and
the cytoplasm and Satoshi presented extensive experiments
demonstrating both transcriptional (nuclear) and post-
transcriptional (cytoplasmic) regulation of CCN2. Further
work from this group, presented by Dr Ogawara, demon-
strated that mi-RNA 18a acts on CCN2 via the 3’-UTR and
regulates human chondrocytic differentiation. This work
now introduces a new level of CCN regulation that should
get increasing attention. In a change of cellular context, Dr
J. Cell Commun. Signal. (2008) 2:95–100
DOI 10.1007/s12079-009-0036-8
A. E. Irvine (*)
Centre for Cancer Research and Cell Biology,
Queen’s University Belfast,
Belfast BT9 7BL, N Ireland
e-mail: s.irvine@qub.ac.uk
B. Perbal
L’Oreal R & D,
Clark, NJ 07066, USA
H. Yeger
Department of Paediatric Laboratory Medicine,
Hospital for Sick Children,
Toronto, CanadaCabello-Verrugio (Santiago, Chile) presented work on the
regulation of CCN2 by TGF-b and LPA in skeletal muscle
cells in parallel with other studies from his lab suggesting
dependency on decorin and involvement of the endocytic
receptor LRP-1. He used the C2C12 myoblast cell line to
show a dose-dependent induction of CCN2 where the
induction is mediated classically through TGFbR1 and
SMAD2/3.
The final paper in this session was given by Dr Yasuda
(Boston, USA) and described the use of ChIP on CHIP
analysis to identify a SOX9 binding site in the promoter
region of CCN2.
Brahim Chaqour (New York, USA) described elegant
studies to examine the mechanical regulation of CCN1 in
smooth muscle cells. Myocardin related transcription factor
(MRTF-A) was shown to shuttle between the nucleus and
the cytoplasm being localised in the cytoplasm in unstimu-
lated cells and accumulating in the nucleus of mechanically
stimulated cells. He showed that nuclear MRTF-A acts in
concert with P300/CBP to regulate CCN1. Periostin is not a
member of the CCN family but is a novel secreted
matricellular protein with a similar expression pattern to
CCN2. Douglas Hamilton (Ontario, Canada) described
experiments showing that periostin expression was in-
creased in mechanically stressed skin fibroblasts and was
also increased in cutaneous wound repair. Periostin seems
to become extracellular in various pathologies and its mode
of action and expression suggest that it may have
similarities to the CCN family. Interestingly, periostin binds
to CCN3. Lan Wei (Boston, USA) constructed a series of
plasmids expressing each domain of CCN5 alone and in
combinations both with and without the secretory peptide.
By using fluorescently tagged constructs they were able to
show that non-secreted forms of the Von Willebrand type C
(V) domain alone, Thrombospondin type-1 domain (T)
alone and IV, VT and IVT domains were imported into the
nucleus; the same constructs containing an N-terminal
signal peptide were not detected. They are currently
applying monoclonal antibodies against specific domains
of CCN5 to further elucidate its mode of action. This
session finished with a return to the topic of CCN2
regulation. Hirokazu Okada (Saitama, Japan) identified a
20bp region in the mouse CCN2 promoter which is bound
by PolyADP-Ribose Polymerase-1 (PARP-1) and named it
PARP Binding Element (PBE). Since PARP-1 is a higher
order modifier of histones and CCN2 is the main mediator
of the pro-fibrotic effects of TGF-β in fibrotic kidneys, this
may open up new anti-fibrotic therapeutic targets for this
disorder.
The session on Osteogenesis and Chondrogenesis was
opened by Professor Masaharu Takigawa (Okayama, Japan)
who described a transgenic mouse model in which the
CCN2 gene was overexpressed in cartilage under the
control of the type II collagen promoter. He showed that
this lead to accelerated endochondral ossification by
promoting proliferation and differentiation of chondrocytes.
He also compared wild-type and CCN2 null mice and
showed that CCN2 is also required for normal intra-
membranous bone development. This theme was carried
on by a presentation from Fayez Safadi (Philadelphia,
USA) who has developed a transgenic mouse model in
which CCN2 is overexpressed in cells of the osteoblast
lineage. By comparing moderate to high level overexpress-
ing mice he was able to show that moderate levels of CCN2
promote bone formation whilst high levels have an opposite
effect and promote osteoclast formation. Faith Hall-Glenn
(Los Angeles, USA) described a further mouse model in
which CCN1 and CCN2 were specifically knocked out in
cartilage. Cartilage specific loss of CCN1 is perinatal lethal
although the skeletons of the mice have only minor
alterations whilst the double knockout animals have a
much more severe phenotype. The phenotypes of the
animals developed by Takigawa and Hall-Glenn were quite
different reflecting the different strategies used to control
gene expression. These animal models provide exciting
new tools to investigate the functional roles of the CCN
proteins. Ken-ichi Katsube (Tokyo, Japan) constructed
CCN3 deletion mutants lacking the CT domain (del CT)
and used these to study NOTCH and BMP signalling in the
mouse osteogenic cell line, Kusa-A1. The CT domain is
responsible for binding NOTCH yet the delCT mutant was
still able to activate downstream NOTCH signalling path-
ways and was able to bind BMP. These results suggest that
the inhibitory effect of CCN3 on osteogenesis is mediated
by both NOTCH and BMP signalling pathways. Andrew
Leask (Ontario, Canada) grew mesenchymal cells in a
micromass model culture system for his studies on
chondrogenesis. FAK/src signalling mediates cell adhesive
properties and inhibition of this pathway lead to increased
expression of CCN2 and chondrogenic matrix associated
genes in wild type cells; CCN2 null cells did not respond.
These results suggest that CCN2 operates downstream of
FAK/src and that loss of FAK/src is critical for chondro-
cytic differentiation.
Kruppel-like factor 15 (KLF-15) is expressed in both
cardiomyocytes and fibroblasts and is reduced by pro-
hypertrophic stimuli both in vitro and in vivo. Mukesh Jain
(Cleveland, USA) used a rat ventricular fibroblast cell
model to show that KLF-15 inhibits CCN2 by preventing
recruitment of P/CAF to the promoter region. He also
generated KLF-15 null mice and found increased levels of
CCN2 and collagen in the heart as a result of mechanical
stress. These results suggest that KLF-15 plays a key role in
the regulation of cardiac stress. Mark Erwin (Toronto,
Canada) presented some fascinating studies using canine
models to explore biological therapies for degenerative disc
96 A.E. Irvinedisease. Mongrel dogs which do not get disc problems
retain a notochordal cell rich region, and these cells secrete
CCN2 which can then upregulate aggrecan expression in
chondrocytes. In contrast, Beagles are prone to disc
degeneration similar to ageing humans. This is likely to
be a promising non-rodent animal model for the CCN field.
Karen Lyons (Los Angeles, USA) used a CCN2-/- mouse
model and mice with CCN2 specifically knocked out in
endothelial cells to look for effects on angiogenesis. She
showed that the vascular system develops normally in these
mice initially but that vascular remodelling is defective,
probably due to defective basement membrane assembly.
Of further relevance here is the disruption in pericyte/
endothelial cell interactions with broader implications for
stem cell biology. Ursula Kees (Perth, Australia) has found
markedly elevated levels of CCN2 in paediatric acute
lymphoblastic leukaemia (ALL). She presented data show-
ing that CCN2 may be involved in the interaction of the
ALL cells with the bone marrow microenvironment and is
currently investigating the underlying mechanisms in-
volved. Gene enrichment analysis suggested multiple genes
upregulated in ALL as in other cancers.
The first of the pathobiology sessions started with a
series of presentations examining the role of CCN proteins
in normal and wounded skin. Laure Rittie (Michigan, USA)
used laser capture micro-dissection coupled with real time
PCR and immunocytochemistry to study CCN expression
in normal skin and following wounding by thermal
ablation. She showed very clearly that the CCN proteins
are expressed in a cell type and stage specific manner
during wound healing. She also observed CCN expression
in nuclei during injury and a marked decrease in CCN3
after wounding and return to normal levels in the healing
phase thus supporting the notion of CCN proteins operating
alternately and in balance. Following on from this Andrew
Leask specifically examined CCN2 using a novel transgen-
ic knock-in mouse model with a GFP gene inserted
between the endogenous CCN2 promoter and gene. Using
this strategy Andrew was able to show that, on wounding,
CCN2 induction parallels the appearance of myofibroblasts
and that pericytes also express CCN2 and contribute to
myofibroblast activity. This data further begs the question
of whether reactive mesenchymal phenotypes all exploit
CCN2 for repair processes. Taihao Quan (Michigan, USA)
presented studies on UV and chronologically aged skin
showing that CCN1 plays a role in aberrant dermal collagen
homeostasis. The thinking is that changes in CCN1 modify
the TGFb mediated effects on collagen synthesis and thereby
structurally change skin. Interestingly, he also found that
retinol had the potential to reverse many of these effects
consistent with its application in anti-ageing skin care
products. Kirsten Bielefeld (Toronto, Canada) gave an
excellent presentation on her doctoral studies of β-catenin
during wound healing. She used primary dermal fibroblasts
to show that the extracellular matrix acts as a feedback loop
to regulate β-catenin during wound repair. DEL1, a further
matricellular protein with an expression pattern similar to
CCN1 and CCN2, was shown to enhance bone fracture
healing (Yang, Stanford, USA). In contrast to the CCN1 and
CCN2 mutants, DEL1 knockout mice have normal skeletons
but heal fractures with less bone. This may reflect a role for
DEL1 in preventing premature apoptosis of the hypertrophic
cartilage during endochondral ossication. Cutler (Maryland,
USA) used a mouse mammary epithelial cell line (HC-11) to
examine the role of CCN2 during lactogenic differentiation.
She showed that CCN2 levels increased more than ten fold
during differentiation, CCN2 enhances HC-11 differentia-
tion, blocked by CCN2 siRNA, and that effects are mediated
via activation of the β-1 integrin mediated adhesion
complexes and integrin dependent signalling pathways.
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investigate the role of CCN2 in heart disease. CCN2 was
shown to act as a survival factor in these mice resulting in
reduced infarct size and improved recovery. Apparently the
cardioprotection exhibite db yC C N 2i sm e d i a t e db ya
complex regulatory network. Stephen Twigg (Sidney, Aus-
tralia) followed on from this with studies of CCN2 in
diabetic cardiomyopathy. In contrast to the previous study,
CCN2 was found to mediate the adverse effects of high
glucose and free fatty acids in the H9C2 cardiomyocyte cell
line. Treatment with a specific trkA inhibitor, K252a,
blocked the effects of CCN2 on hypertrophy and apoptosis,
an observation supporting the previous report by Wahab et
al. (2005), suggesting that CCN2 is acting via the trkA
pathway. The search for new biomarkers in systemic
sclerosis was explored by Robert Lafyatis (Boston, USA)
who found that TGF-β regulated genes, including CCN2,
are increased in the skin of patients with scleroderma and
that some of these genes (COMP and TSP1) correlated with
a modified Rodnan skin score. Using the tight skin mouse
(Tsk) model he also found that CCN3 was highly expressed
and postulated that it counter-regulates fibrillin matrix fibre
assembly and deposition.
Takako Hattori (Okayama, Japan) used a combination
of in vitro and in vivo studies to show that SOX9 binds to
the enhancer region of the CCN2 gene. She then used
mouse models in which CCN2 was specifically overex-
pressed in skin or cartilage to demonstrate a stimulatory
feedback loop involving CCN2, SOX9 and aggrecan.
CCN2 colocalized with aggrecan on the cell surface. Joshua
Russo (Boston, USA) described a new model system
developed to study leiomyoma in vivo. Fresh human fibroid
tissue is broken up and resuspended in a matrigel/ collagen
I mixture before subcutaneous injection into mice. Follow-
ing hormone supplementation, human smooth muscle cells
grow out of the injection site where they acquire a blood
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excellent system in which to study the effects of CCN5 in
fibroids. In addition, in tumor xenograft models he showed
that CCN5 slowed down tumor growth with reduction in
the tumor vascular architecture. Shiwen (London, England)
investigated the mechanisms linking microvascular damage
to the fibrogenic system in patients with scleroderma (SSc).
He found that endothelin-1 stimulated pericytes (a multi-
potent phenotype) and fibroblasts to produce CCN2 and
collagen, via ERK1/2 mediated signalling, and that peri-
cytes acquire fibroblast markers on long term culture. This
suggests that pericytes may contribute to the fibrosis
observed in SSc and must be considered when developing
new treatment strategies. Enrique Brandan (Chile) used a
mouse model for Duchenne muscular dystrophy in which
exercise protocols induce fibrosis and also lead to an
increase in CCN2. He used this system to show that the
proteoglycan, decorin, can interact with CCN2 inhibiting
the fibrotic action. Gingival fibrosis is a clinical problem
which often occurs as a side effect of medication such as
cyclosporin. In the first of two presentations from Boston,
Alpdogan Kantarci showed that CCN2 is increased at both
the mRNA and protein levels in drug induced gingival
fibrosis and examined the role of CCN2 in promoting
fibrotic lesions. Philip Trackman then described some
beautiful studies in which he delineated the mechanisms
underlying the problem and designed a dual pronged
treatment strategy using lovastatin and forskolin to reduce
TGF-β stimulated CCN2 levels in gingival cells. Bruce
Riser (Chicago, USA) used an in vitro model of renal
fibrosis to look for endogenous inhibitors of CCN2 and
explore the possibility of interaction with other CCN family
members. He found that CCN3 (either provided exoge-
nously or overexpressed) downregulates CCN2 activity in
mesangial cells and blocks ECM overaccumulation stimu-
lated by TGFβ thus providing an opportunity for therapeu-
tic intervention. This inverse relationship between CCN3
and CCN2 is in agreement with the recently published
results by Kawaki et al. (2008). David Brigstock (Colum-
bus, Ohio) has developed an exciting therapeutic strategy to
target fibrosis in a mouse model of hepatic fibrosis and
evaluated anti-CCN2 therapy in both a preventative and
curative setting (before or after onset of collagen deposi-
tion). Liposomes containing CCN2 siRNA, when coated
with a synthetic peptide to ensure they homed to activated
hepatic stellar cells, proved to be effective as an anti-
fibrotic agent. The ready delivery of CCN2 siRNA across
multiple tissue barriers opens up possibilities for transla-
tional studies in the CCN field. The final presentation of
this session was from Margarete Gopelt-Struebe (Erlangen,
Germany) who investigated the hypoxia-induced regulation
of CCN2. Hypoxia was induced by the DMOG inhibitor of
PHD2 and thereby activation of HIF1a. She demonstrated
that regulation of CCN2 by hypoxia is cell type dependent
and involves the FoxO family of transcription factors.
Interestingly, she showed an additive effect of DMOG and
TGFb a more complex regulatory situation during injury.
In the spirit of promoting the bridging of two fields,
CCN and Matrix, a new feature of the workshop was a
special session entitled ‘From Matricellular to Extracellu-
lar’ (see http://ccnsociety.com/award.html). Three eminent
clinician-scientists from Toronto put the entirety of the
conference in to context by presenting the human con-
sequences of dysregulation in the extracellular matrix
system. Aleksander Hinek described how defective produc-
tion of components involved in elastin microfibril assembly
contributes to numerous skeletal and vascular disorders.
William Cole focused on how studies of rare genetic
disorders have led to greater understanding of the genes
required for normal development of bone and cartilage.
Ren-Ke Li gave an inspirational talk on the potential of
myocardial cell therapy. Through detailed studies with
animal models he is teasing apart the underlying mecha-
nisms for cell based therapy as an approach to matrix
remodelling. Katherine Sodek has just completed her PhD
and presented the work she carried out on ovarian cancer.
She used a novel 3-D culture system and showed that MT1-
MMP and MMP2 contribute to cell motility and matrix
degradation whilst treatment with TGFβ stimulated spher-
oid formation and was associated with increased invasive
capacity. This was an excellent session and set the clinical
framework of matricellular disorders.
CCN3 came to the fore in the second pathobiology
session of the meeting. Vivianna Vallachi (Milan, Italy)
found that increased CCN3 expression was associated with
poor prognosis in metastatic melanoma. Analysis of CCN3
in cultures of cells from melanoma lesions showed
heterogeneous expression of the 46 kDa (mostly cytoplas-
mic) and 32 kDa (nuclear) proteins but this was not
associated with specific CCN3 gene mutations; however,
CCN3 polymorphisms were noted. Xenotransplanatation
studies in immunodeficient mice showed a higher meta-
static potential in CCN3 overexpressing cells and a greater
resistance to induction of apoptosis by cancer chemother-
apeutic drugs. In contrast, CCN3 expression is down-
regulated as a result of BCR-ABL kinase activity in
Chronic Myeloid Leukaemia (CML; Mc Callum, Belfast,
Ireland). Increased CCN3 expression levels resulted in
decreasing levels of phosphorylated ERK reducing cell
proliferation whilst also increasing levels of cleaved
caspase 3 and restoring induction of apoptosis. Primary
human CML cells demonstrated growth inhibition in
response to recombinant CCN3 which may be important
for developing additional therapeutic strategies. Perbal et al.
(Paris, France and Bologna, Italy) examined CCN1-3 to
evaluate their prognostic value in osteosarcoma and Ewings
98 A.E. Irvinesarcoma. They found that CCN3 expression was associated
with increased attachment, migration and an aggressive
phenotype and with an increased risk of recurrence and
metastases. A high number of cases expressed a CCN3
variant, lacking the NH3 domain which conferred worse
prognosis for patients receiving chemotherapy and radio-
therapy. Studies of CCN1 in osteosarcoma (A. Sabile,
Zurich, Switzerland) showed it was upregulated in meta-
static osteosarcoma cell lines and also in primary tissues
from patients. CCN1 induced phosphorylation of Akt and
GSK-3b and coincided with localization of p21 in the
cytoplasm. This mechanism effectively activates both pro-
survival and pro-proliferative pathways. CCN3 co-localises
with a core component of gap junction complexes,
connexin43 (Cx43). These observations are in agreement
with previously published work reporting the co-local-
isation of CCN3 and Cx43 ( Fu et al. 2004; Gellhaus et al.
2004).Wun-Chey Sin (Vancouver, Canada) found Cx43 is
down-regulated in aggressive breast tumours and Cx43
levels positively regulate expression of CCN3. Overexpres-
son of CCN3 in breast cancer cells inhibited cell growth
and was involved in reorganization of the actin cytoskele-
ton and re-distribution of focal adhesions. Further work on
breast cancer was discussed by Ruth Lupu (Rochester,
USA). She found that CCN1 expression is correlated with
advanced disease in breast cancer and induces a taxol
resistant phenotype. CCN1 upregulates expression of the
αvβ3 integrin; functional blockade of αvβ3 with a
synthetic chemical peptidomimetic of the RGD motif is
cytotoxic for CCN1 expressing breast cancer cells. Dis-
rupting the interaction of CCN1 and αvβ3r e g a i n e d
sensitivity to taxol. Zoledronic acid, an aminobisphospho-
nate, inhibits CCN1 expression and reduces anchorage
independent cell growth as well as disrupting vimentin
distribution. These findings present a novel therapeutic
strategy for targeting metastatic breast cancer. Kallikreins
(KLKs) are a multi-gene family of secreted serine pro-
teases. KLKs and kallikrein related peptidases have
important implications in regulating cancer cell growth,
angiogenesis, invasion and metastasis. Yves Courty (Tours,
France) found that KLK12 could cleave CCN1 from the
surface of a tumour cell line. He went on to show that all
members of the CCN family can be digested with KLKs,
notably CCN1 and CCN5 by KLK12 and KLK14, CCN3
by KLK5, 12 and 14. Further work will ascertain the
functional CCN properties before and after degradation.
The fact that KLK activity released smaller CCN fragments
opens up new possible roles for CCN proteins in the
multiple disease states where KLKs figure prominently.
Finally Sushanta Banerjee (Kansas, USA) presented his
investigations of the role of mi-RNA-10b in metastatic
breast cancer. CCN5 is expressed in non-invasive breast
cancer cell lines whilst it is not detected in invasive breast
cancer. Silencing CCN5 expression in MCF7 cells,
increased miR-10b expression and increased cell migration
and invasiveness. The mechanism driving invasive capacity
is thought to involve down-regulation of CCN5 expression
causing increased levels of miR-10b and the transcription
factor, twist, leading to increased levels of HIF1α and
enhanced motility.
The final session of the meeting featured presentations by
the Springer Scholarship awardees. Wei Huang (Michigan,
USA) constructed a CCN6 deficient human mammary
epithelial cell line model and used this to look at the effects
onE-cadherin.CCN6inhibitionwasassociatedwithdecreased
E-cadherin expression which was shown to be mediated by
upregulation of SNAIL and ZEB1. These observations are
important since loss of E-cadherin is associated with de-
differentiation, invasion and metastasis. Since CCN3 is
associated with Cx43 perhaps CCN proteins play distinct and
important roles in organization of cell junction complexes not
yet fully appreciated. Further studies in breast cancer were
presented by Ingrid Espinoza (Chicago, USA) who examined
therole ofCCN1 in the hormonalresponse.She useda mutant
CCN1 construct with substitutions in the α6β1 binding
domain to support a possible role for CCN1 as a co-activator
of ER, involved in the transcriptional activation of prolifer-
ative and survival ERE-genes in breast cancer cells. Of
relevance here was the data supporting the posited nuclear
role for CCN proteins in transcriptional events. Takanori
Eguchi (Okayama, Japan) described a novel role for matrix
metalloproteinase (MMP)-3 as a promoter of extra-cellular
matrix production through CCN2 trans-activation. MMPs are
conventionally regarded as extracellular acting proteases but
Takanori showed that MMP-3 can be translocated into the
nucleus and bind the Transcription Enhancer Dominant In
Chondrocytes (TRENDIC) to regulate CCN2. All three
presentations were of an extremely high standard and the
recipients were to be congratulated.
Lester Lau concluded the meeting with a masterful
exposition on CCNs and inflammation, pulling together
many strands of interest that permeated the meeting,
particularly the exciting new model systems which have
been developed and progress towards translational applica-
tions. With much to challenge and stimulate us, and after
closing remarks by Dr. Yeger and Prof Perbal, Dr. S. Irvine
(Belfast, Ireland) extended an enthusiastic invitation to the
6th ICCNS workshop to be held in Belfast, 2010.
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